// OVERVIEW
Paris-based biotech developing ulcerative colitis treatment whose stock dropped 30%+ on clinical data showing cancer cases at higher dose.
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
mention·Axios Pro Rata·JUNE 2, 2026
“Some suitors might view this red flag as a buying opportunity, but the likeliest scenario is that everyone waits for a fuller data release in October.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.